Furthermore, LASS2 expression levels were negatively associated with cisplatin IC50 values based on transcriptional and drug sensitivity data of 19 bladder cancer cell lines from the GDSC database (Fig. 1E). The gene discussed is CERS2; the disease is urinary bladder carcinoma.